Advertisement
Screener

MACROGENICS, INC. (MGNX) Overview

MACROGENICS, INC. (MGNX) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 0.31; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.58; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 0.27; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.57; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$1.26$1.67$2.21$2.92$3.86$5.102025-09-292026-09-29$1.01$1.88$3.52$6.58$12.29$22.972021-09-292026-09-29$1.01$2.08$4.28$8.81$18.16$37.412016-09-292026-09-29$1.01$2.13$4.49$9.47$20.00$42.222013-10-102026-09-29$1.01$2.13$4.49$9.47$20.00$42.222013-10-102026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$3.77
Previous close
$4.06
Change
-$0.29
Change (%)
-7.14%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

MGNX
+134.16%
S&P 500
(m)

1 year

MGNX
+115.43%
S&P 500
(m)

3 years

MGNX
-19.10%
S&P 500
(m)

5 years

MGNX
-81.60%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual 0.31

-0.73-0.42-0.120.190.4931 Mar 2025: estimate (m); actual -0.6531 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.5730 Jun 2025(m)30 Sept 2025: estimate (m); actual 0.2730 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.5831 Mar 2026(m)30 Jun 2026: estimate (m); actual 0.3130 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)0.31(m)(m)
1 Jan 202631 Mar 2026(m)-0.58(m)(m)
1 Jul 202530 Sept 2025(m)0.27(m)(m)
1 Apr 202530 Jun 2025(m)-0.57(m)(m)
1 Jan 202531 Mar 2025(m)-0.65(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -1.18

-3.45-2.58-1.71-0.840.0331 Dec 2021: estimate (m); actual -3.3731 Dec 2021(m)31 Dec 2022: estimate (m); actual -1.9531 Dec 2022(m)31 Dec 2023: estimate (m); actual -0.1531 Dec 2023(m)31 Dec 2024: estimate (m); actual -1.0731 Dec 2024(m)31 Dec 2025: estimate (m); actual -1.1831 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-1.18(m)(m)
1 Jan 202431 Dec 2024(m)-1.07(m)(m)
1 Jan 202331 Dec 2023(m)-0.15(m)(m)
1 Jan 202231 Dec 2022(m)-1.95(m)(m)
1 Jan 202131 Dec 2021(m)-3.37(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 32.83M ■ Earnings 19.52M — Profit margin 59.44%

-49.93M-178.0%-4.62M-69.5%40.69M39.0%85.99M147.5%30 Sept 2025: revenue 72.84M; earnings 16.82M; profit margin 23.09%30 Sept 202531 Dec 2025: revenue 41.23M*; earnings 60.39M*; profit margin 146.48%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 20.77M; earnings -36.77M; profit margin -177.01%31 Mar 202630 Jun 2026: revenue 32.83M; earnings 19.52M; profit margin 59.44%30 Jun 2026

31 Dec 2025 ■ Revenue 149.50M ■ Earnings -0.07M — Profit margin -0.05%

-152.36M-79.8%-40.06M-52.9%72.24M-25.9%184.54M1.0%31 Dec 2022: revenue 151.94M; earnings -119.76M; profit margin -78.82%31 Dec 202231 Dec 2023: revenue 58.75M; earnings -0.01M; profit margin -0.02%31 Dec 202331 Dec 2024: revenue 149.96M; earnings -0.07M; profit margin -0.04%31 Dec 202431 Dec 2025: revenue 149.50M; earnings -0.07M; profit margin -0.05%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$3.77(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$3.77High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning MGNX

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$59.95M
Profit margin
34.23%
Return on assets · 12 month
20.29%
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
293.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
553.88K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-8.50%*
Total return · month
-8.72%*
Total return · quarter
-22.43%*
Total return · half year
28.67%*
Total return · year to date
134.16%*
Total return · 1 year
115.43%*
Total return · 3 years
-19.10%*
Total return · 5 years
-81.60%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$175.14M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

MACROGENICS, INC. Overview

View more →

(m)

(m)

SEC CIK
1125345
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
9704 MEDICAL CENTER DRIVE, Rockville, Maryland, 20850, United States
Fiscal year end
1231
Phone
301-251-5172

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35